Dementia Research Centre, Institute of Neurology, UCL, London, UK.
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Nat Commun. 2024 Jul 5;15(1):5661. doi: 10.1038/s41467-024-49949-9.
A major challenge in Parkinson's disease is the variability in symptoms and rates of progression, underpinned by heterogeneity of pathological processes. Biomarkers are urgently needed for accurate diagnosis, patient stratification, monitoring disease progression and precise treatment. These were previously lacking, but recently, novel imaging and fluid biomarkers have been developed. Here, we consider new imaging approaches showing sensitivity to brain tissue composition, and examine novel fluid biomarkers showing specificity for pathological processes, including seed amplification assays and extracellular vesicles. We reflect on these biomarkers in the context of new biological staging systems, and on emerging techniques currently in development.
帕金森病的一个主要挑战是症状的可变性和进展速度的差异，这是由病理过程的异质性所支撑的。因此，迫切需要生物标志物来进行准确的诊断、患者分层、监测疾病进展和精确治疗。虽然之前这些标志物并不存在，但最近已经开发出了新的成像和液体生物标志物。在这里，我们考虑了对脑组织成分敏感的新成像方法，并研究了对病理过程具有特异性的新型液体生物标志物，包括种子扩增测定和细胞外囊泡。我们在新的生物学分期系统的背景下对这些生物标志物进行了反思，并探讨了目前正在开发的新兴技术。
